ITCI: מחיר למכירות Intra-Cellular

The implementation of "green chemistry" principles for environmental protection is complemented by basic compliance with laboratory waste disposal standards for Intra-Cellular Therapies (ITCI). The P/S ratio history on the GURU.Markets chart visualizes this process, where 20.60 serves as the current metric level. Business stability is supported by international biocomponent logistics and the diversification of research centers, ensuring high long-term profitability for the company.

The P/S multiple relates market capitalization to sales volume, reflecting investor expectations regarding the business's future sector share. Analyzing the divergence of the P/S from its historical average allows for the identification of asset overvaluation, which is critical for Intra-Cellular Therapies (ITCI), where the high stock price is justified by colossal R&D expenditures and the potential for leadership in neurobiology.